Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038578 · ClinicalTrials.gov registry record · Phase 2
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
A Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, sponsored by Toray Industries.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT06038578: Recruiting Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, sponsored by Toray Industries.
NCT06038578 is a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma that is actively recruiting participants, run by Toray Industries. The registered enrollment target is 146 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06038578, a Phase 2 study of Gastric Cancer and Gastric Adenocarcinoma, is actively recruiting participants, sponsored by Toray Industries.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Primary Outcome
Progression free Survival (PFS) is defined as time from the date of randomization to the date of progressive disease or death due to any cause based on Independent Central Review.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Ramucirumab
- BIOLOGICAL TRK-950
Study Locations (20)
Texas
- Texas Oncology Arlington North - Arlington
- Texas Oncology Bedford - Bedford
- Texas Oncology Dallas Methodist - Dallas
- Texas Oncology Dallas Medical City - Dallas
- Texas Oncology Dallas Presbyterian - Dallas
- Texas Oncology Methodist Charlton Cancer Center - Dallas
- Texas Oncology-Sammons Cancer Center - Dallas
- Texas Oncology Fort Worth Cancer Center - Fort Worth
- Texas Oncology Grapevine - Grapevine
- Texas Oncology Plano East - Plano
- Texas Oncology Plano West - Plano
California
- City of Hope - Duarte
- City of Hope at Orange County Lennar Foundation Cancer Center - Irvine
- University of California, Los Angeles - Santa Monica
Other
- National Cancer Center Hospital - Chūōku
- Osaka International Cancer Institute - Chūōku
- National Cancer Center Hospital East - Kashiwa
Kanagawa
- Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center - Yokohama
Saitama
- Saitama Prefectural Hospital Organization Saitama Cancer Center - Shinden
Shizuoka
- Shizuoka Cancer Center - Nagaizumi-cho
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT06038578 shows while recruiting
NCT06038578 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (54% lower).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.
NCT06038578 names 20 study sites across 6 states, led by Texas, California, Other.
Frequently Asked Questions
What is clinical trial NCT06038578 about?
NCT06038578 is a clinical study titled "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer". This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarc...
What is the current status of trial NCT06038578?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2023-10-04. Estimated completion is 2026-06-30.
What conditions does trial NCT06038578 study?
This clinical trial studies the following conditions: Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT06038578?
The interventions under investigation include: Paclitaxel (DRUG), Ramucirumab (DRUG), TRK-950 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06038578?
This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038578 being conducted?
This trial has 20 study locations across California, Texas, Kanagawa, Saitama, Shizuoka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06038578's enrollment target sits among peer trials
146 63rd of 153 higher than 91 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI